Business Insider: Entrada Therapeutics’ Promising Phase 1 Trial and Broad Tissue Distribution Profile Underpin Buy Rating
H.C. Wainwright analyst Boobalan Pachaiyappan reiterated a Buy rating on Entrada Therapeutics Inc (TRDA – Research Report) today and set a price target of $25.00. Boobalan Pachaiyappan’s Buy rating ...
Entrada Therapeutics’ Promising Phase 1 Trial and Broad Tissue Distribution Profile Underpin Buy Rating
Dom Casamento is a producer for CNBC's Halftime Report, located at the network's Global Headquarters in Englewood Cliffs, N.J. He also contributes to CNBC.com. Got a confidential news tip? We want to ...